Mushrooms, IBS & FODMAPs
54% of IBS patients
In a 2024 blinded reintroduction trial, mannitol, the primary FODMAP in mushrooms, triggered IBS symptoms in 54% of patients comparable to fructans (56%), the best-known IBS dietary trigger.
Van den Houte et al., Gastroenterology, 2024
#1 ranked
low-FODMAP diet for all IBS symptom endpoints per 2022 network meta-analysis (Black et al., Gut)
2025
year mushroom blends were shown to restore butyrate in IBS-specific microbiomes ex vivo (Van den Abbeele)
oyster mushrooms
the only fresh mushroom with no serving size restriction on a low-FODMAP diet (Monash University)
Van den Houte et al., Gastroenterology, 2024
View as image ↗In a 2024 blinded reintroduction trial published in Gastroenterology, researchers gave IBS patients capsules containing specific FODMAP types without revealing which was which, then measured symptom responses. Mannitol, the sugar alcohol found in high concentrations in mushrooms, triggered symptoms in 54 percent of IBS patients.[1] Only fructans, the most studied IBS dietary trigger, scored slightly higher at 56 percent. Most recommendations against mushrooms for IBS patients rest directly on this finding.
The research on mushrooms for IBS contains a genuine paradox. Mushrooms contain both a compound that reliably worsens IBS symptoms (mannitol, a small fermentable sugar alcohol) and a compound that has been shown in clinical trials to improve IBS symptoms (beta-glucan, a large fiber molecule). These two compounds are in the same mushroom but behave completely differently in the gut. Which one dominates depends on which mushroom species you eat, how it's prepared, and whether you're consuming whole food or an extract.
Neither "mushrooms are bad for IBS" nor "mushrooms help IBS" is the whole story. The answer depends on what you mean by mushrooms. This article is part of the broader guide to how mushrooms feed and support the gut microbiome, which covers the full picture of mushrooms and digestive health.
Key Takeaways
- Van den Houte et al. (2024) confirmed in a blinded reintroduction RCT that mannitol, the primary FODMAP in mushrooms, triggered IBS symptoms in 54% of patients, one of the highest trigger rates of all FODMAPs tested[1]
- Halmos et al. (2014) showed in an RCT (n=30 IBS patients) that 21 days on a low-FODMAP diet reduced IBS symptom scores from 44.9 to 22.8, validating that mannitol avoidance genuinely reduces symptoms, not just theoretically[2]
- The key species split: button, cremini, and portobello mushrooms are high-FODMAP (high mannitol); oyster mushrooms are low-FODMAP at any serving size; canned champignons are low-FODMAP at 75g drained
- Ciacci et al. (2011) found that a beta-glucan supplement significantly improved bloating, flatulence, and abdominal pain in 50 IBS patients compared to 40 untreated controls[5]
- Van den Abbeele et al. (2025) showed that a mushroom blend restored butyrate production in ex vivo IBS microbiome cultures and improved gut barrier integrity, the first IBS-specific microbiome data for mushroom compounds[7]
- The mannitol problem and the beta-glucan benefit are in different molecular fractions of the same mushroom: avoiding high-mannitol species or using extracts captures the benefit while bypassing the trigger
What FODMAPs Are, and Why Mannitol in Mushrooms Is the Key Variable
FODMAP is an acronym for a set of short-chain carbohydrates that share two properties: they are poorly absorbed in the small intestine, and they are fermentable, meaning gut bacteria can break them down and produce gas as a byproduct. The F stands for fermentable, the ODMAP covers specific types: oligosaccharides (fructans and galactooligosaccharides), disaccharides (lactose), monosaccharides (fructose), and polyols (mannitol, sorbitol, and similar sugar alcohols).
When these compounds reach the large intestine unabsorbed, two things happen. First, because they are osmotically active, they draw water into the gut, contributing to diarrhea and loose stools. Second, gut bacteria ferment them and produce gas, contributing to bloating, pain, and flatulence. In people with IBS, whose guts are more sensitive to distension and whose motility patterns are often abnormal, both effects produce disproportionately severe symptoms.
Mannitol is the FODMAP type most concentrated in mushrooms. It is a sugar alcohol, naturally present in many fungi. Halmos and colleagues (2014) ran one of the landmark FODMAP trials: in a crossover RCT with 30 IBS patients and 8 healthy controls, 21 days on a low-FODMAP diet reduced IBS symptom scores from 44.9 to 22.8 on a typical Australian diet, roughly halving symptom burden.[2] Black and colleagues (2022) synthesized the entire literature in a network meta-analysis published in Gut and found the low-FODMAP diet ranked first for all IBS symptom endpoints tested across dietary approaches.[3] The diet works. Mannitol avoidance is a meaningful part of why.
Mannitol: Confirmed as a Trigger in 54% of IBS Patients
Before Van den Houte and colleagues (2024), the evidence that specific FODMAPs trigger IBS was largely inferred: the low-FODMAP diet as a whole improved symptoms, so individual FODMAPs were assumed to be responsible. The blinded reintroduction design directly tested which specific FODMAP types were doing the triggering.[1]
Participants who had responded to the low-FODMAP diet were then given individually identified FODMAP types in capsule form, blinded so neither patients nor researchers knew what was being taken. Mannitol triggered symptoms in 54 percent of tested patients. Fructans (the sugar chains in wheat, onion, and garlic) triggered 56 percent. Lactose and fructose triggered substantially fewer patients.
This confirms two things specific to mushrooms. First, mannitol is not a minor or theoretical FODMAP concern: it is one of the two most impactful dietary triggers for people with IBS. Second, the symptom response to mannitol is individual: 46 percent of IBS patients in this study did not react to mannitol. This means that some IBS patients can eat moderate amounts of mannitol-containing mushrooms without issue, while others will have strong reactions. The 54 percent figure is a population-level risk estimate, not a universal rule.
The Species Split: Why "Can I Eat Mushrooms?" Has No Simple Answer
The FODMAP content of mushrooms varies dramatically by species, and in some cases by preparation method.
The most commonly eaten mushrooms, button, cremini, and portobello, are all Agaricus bisporus at different growth stages. Blumfield and colleagues (2020) documented the nutritional composition of Agaricus bisporus extensively: it is high in mannitol and is the species most likely to trigger IBS symptoms when eaten fresh.[4] Given that Agaricus bisporus represents the large majority of all mushroom consumption, this is the practical explanation for why mushrooms have a reputation as an IBS problem.
Oyster mushrooms (Pleurotus ostreatus) are a different story. Monash University's FODMAP testing database, the clinical reference used by registered dietitians globally, classifies oyster mushrooms as low-FODMAP at any serving size. They can be eaten freely on a low-FODMAP diet without mannitol concern.
Several other species are low-FODMAP in specific forms: dried shiitake mushrooms are low-FODMAP at two dried pieces; dried porcini are low-FODMAP at one tablespoon; canned champignons (well-drained) are low-FODMAP at 75 grams. Enoki and king oyster mushrooms are also considered safe in reasonable servings.
The practical guide for which species are safe, and how different preparations affect FODMAP content, is covered fully in the FODMAPs in mushrooms guide and the low-FODMAP mushroom options list.
Preparation Changes the FODMAP Load: The Case for Canned
Mannitol is water-soluble. This is mechanistically important: when mushrooms are cooked in water, boiled, canned, or soaked, mannitol leaches out of the mushroom tissue into the liquid. Discarding that liquid reduces the mannitol load of the mushroom itself.
This is why canned champignons have a different FODMAP classification than fresh button mushrooms: the canning liquid contains mannitol that has leached out during the processing and heat treatment. Eating the drained mushrooms means eating a fraction of the original mannitol content.
The same principle applies to cooking fresh mushrooms in water and discarding the liquid. Sauteing without liquid does not reduce mannitol content because nothing is extracting it from the tissue; boiling or simmering in water and discarding the broth does.
For IBS patients who want to include mushrooms in cooked dishes, this preparation difference is practically significant: a well-drained, canned mushroom is a different FODMAP exposure than the same species eaten raw or sauteed in oil.
The Opposite Finding: Beta-Glucans and Clinical Evidence for Symptom Benefit
Beta-glucan is a polysaccharide, a large fiber molecule, found throughout mushroom cell walls. It is chemically unrelated to mannitol and functions completely differently in the gut. Beta-glucan is not fermented rapidly by gut bacteria to produce gas. Instead, it acts as a prebiotic: food for beneficial bacteria that then produce beneficial fermentation products including short-chain fatty acids.
Crucially, beta-glucan is not a FODMAP. FODMAPs are short-chain, rapidly fermentable, osmotically active. Beta-glucan is a large, slowly fermentable molecule that does not draw water into the gut in the same way.
Ciacci and colleagues (2011) gave a supplement containing beta-glucan, inositol, and digestive enzymes to 50 IBS patients and compared outcomes to 40 untreated controls over a treatment period.[5] The treated group showed significant improvements in bloating, flatulence, and abdominal pain, the symptoms most strongly linked to intestinal gas. These are the exact symptoms mannitol tends to worsen. A beta-glucan supplement produced the opposite effect: reducing them.
Spagnuolo and colleagues (2017) followed this with a study showing the same beta-glucan plus inositol combination improved overall quality of life in both IBD and IBS patients.[6] The beta-glucan used in both studies was not derived specifically from medicinal mushrooms, but the same beta-glucan type is present in oyster mushrooms, lion's mane, reishi, and other species. For a complete exploration of the supplement pathway for IBS patients, the mushroom supplements and IBS article covers the full clinical evidence and the FODMAP bypass mechanism of extracts.
It is worth noting what the Ciacci and Spagnuolo studies cannot tell us: whether the benefit came from beta-glucan specifically or from the combination product as a whole. Inositol has independent GI effects, and the digestive enzymes component also contributes. What the studies do establish is that beta-glucan-containing supplement combinations improve IBS symptoms, which is directionally consistent with the mechanistic picture.
A 2025 Study: Mushroom Blends Restore the Butyrate Deficit Seen in IBS
In 2025, Van den Abbeele and colleagues published a study using a method that had never been applied to mushrooms in IBS before: they cultured gut microbiomes taken directly from IBS patients outside the body (an ex vivo fermentation approach) and tested what happened when mushroom compounds were added.[7]
The finding: a mushroom blend combined with triacetin (a lipid compound) restored butyrate production in IBS microbiomes and improved markers of gut barrier integrity. Butyrate is a short-chain fatty acid produced when fiber-fermenting bacteria break down prebiotic compounds. It is the primary fuel for the cells lining the gut wall, and it plays a central role in maintaining gut barrier integrity, the tight connections between those cells that prevent bacterial products from crossing into the bloodstream. IBS is associated with reduced butyrate production and compromised gut barrier function; restoring both is a mechanistically meaningful outcome.
Zhao and colleagues (2023) reviewed the broader literature on mushroom polysaccharides and gut microbiota interactions, confirming the consistent pattern: mushroom polysaccharides selectively promote beneficial bacteria and increase short-chain fatty acid production.[8]
The Van den Abbeele 2025 study is ex vivo, not a clinical trial in IBS patients. It does not prove that taking a mushroom supplement improves IBS outcomes. What it establishes is a plausible mechanism in tissue from actual IBS patients, which is a step further than standard cell culture or animal models.
How Both Findings Can Be True at Once
The mannitol finding and the beta-glucan finding are not in conflict. They describe different molecular fractions of the same food.
One Mushroom · Two Molecules · Opposite Effects
Why “Can I Eat Mushrooms?” Has No Single Answer
The same mushroom carries a compound that reliably worsens IBS and a compound shown in trials to improve it. They sit in different molecular fractions and behave in opposite directions. Which one dominates depends on the species and form you eat.
Small, fermentable sugar alcohol · a FODMAP
Draws water into the gut (osmotic) and is rapidly fermented to gas — bloating, pain, loose stools.
Large, slow-fermenting fiber · not a FODMAP
Supplement trials improved bloating, flatulence and abdominal pain in IBS patients[5][6]— the exact symptoms mannitol worsens.
Acts as a prebiotic; a mushroom blend restored butyrate and gut-barrier markers in ex vivo IBS microbiomes[7].
Which form you eat decides which fraction you get
Mannitol is water-soluble, so boiling or canning and discarding the liquid strips it out; hot-water extraction concentrates beta-glucan while diluting mannitol per dose. Individual tolerance varies — 46% of IBS patients did not react to mannitol at all[1].
Source: Van den Houte et al. (2024); Ciacci et al. (2011); Spagnuolo et al. (2017); Van den Abbeele et al. (2025); species/form classifications from the Monash University FODMAP database
When you eat a button mushroom, you get both mannitol (which can trigger IBS symptoms via osmotic water draw and gas fermentation) and beta-glucans (which may benefit IBS via prebiotic effect and butyrate production). The balance of these effects depends on species, serving size, and preparation.
When you take a mushroom extract, the hot-water extraction process concentrates beta-glucan polysaccharides and reduces the relative mannitol content per serving at typical 1-2 gram doses. This is why the Monash University FODMAP database classifies lion's mane powder at 2 grams or less as low-FODMAP, while whole button mushrooms are high-FODMAP. The extract shifts the molecular balance.
For IBS patients, a practical framework emerges: choose oyster mushrooms or well-drained canned mushrooms over fresh button, cremini, or portobello. Use dried shiitake or porcini in small quantities for flavor with reduced FODMAP exposure. Consider mushroom extract supplements as a way to access beta-glucan benefits without the mannitol load of whole mushrooms.
This connects directly to why the prebiotic species that are safest for sensitive stomachs are also among the most gut-beneficial: the species comparison of mushroom prebiotic profiles covers which varieties combine low FODMAP status with high beta-glucan content. It is also worth noting the distinction between IBS and IBD: while the gut-barrier and microbiome mechanisms overlap, mushroom research on inflammatory bowel disease involves different pathologies. The anti-inflammatory mushrooms for IBD article covers that separate body of research. Additionally, chitin, the structural fiber in mushroom cell walls, is a frequently misunderstood compound for IBS patients: the chitin and digestive health article explains why indigestible fiber and FODMAP are not the same thing.
Medical Context
LowThis is educational information, not personalized medical advice
Concern
IBS is a diagnosed medical condition, and FODMAP tolerance is highly individual: in the blinded reintroduction trial, mannitol triggered symptoms in 54% of patients but 46% did not react at all. Population-level classifications cannot tell you how your own gut will respond, and mushroom supplements are not a treatment for IBS.
What the research says
Use the low-FODMAP framework as a structured elimination-and-reintroduction process, ideally guided by a registered dietitian, rather than a permanent restriction. Discuss any mushroom or beta-glucan supplement with your clinician, especially if you take other medications or have another GI diagnosis.
Particularly relevant for: Anyone managing IBS or persistent digestive symptoms
Van den Houte et al., Gastroenterology (2024); Monash University FODMAP database
The Bottom Line
Mushrooms present a genuine paradox for IBS management. Mannitol, concentrated especially in button, cremini, and portobello mushrooms, triggered symptoms in 54% of IBS patients in a 2024 blinded reintroduction RCT. The low-FODMAP diet, validated in multiple RCTs and ranked first in a network meta-analysis, requires avoiding these species in whole-food form. But mushroom beta-glucans, in supplement form, improved IBS bloating and abdominal pain in clinical trials (Ciacci 2011; Spagnuolo 2017), and a 2025 study showed mushroom blends restore butyrate production in IBS microbiomes. Oyster mushrooms, canned mushrooms, and properly dosed extracts offer a path to mushroom's benefits without the mannitol load.
Frequently Asked Questions
Sources & References
- 1. Source details for this reference are not yet available.
- 2RTHM-00596·Halmos, Emma P et al. (2014). “A diet low in FODMAPs reduces symptoms of irritable bowel syndrome..” Gastroenterology.Study breakdown →PubMed →↩
- 3. Source details for this reference are not yet available.
- 4. Source details for this reference are not yet available.
- 5. Source details for this reference are not yet available.
- 6. Source details for this reference are not yet available.
- 7. Source details for this reference are not yet available.
- 8. Source details for this reference are not yet available.